Bio-Techne (TECH) Total Non-Current Liabilities (2014 - 2026)
Bio-Techne (TECH) posted quarterly Total Non-Current Liabilities of $2.5 billion for Q1 2026, down 3.79% year-over-year from $2.6 billion in Q1 2025, and up 1.17% quarter-over-quarter from $2.5 billion in Q4 2025.
Bio-Techne (TECH) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Bio-Techne's Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $2.5 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 3.79% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $2.5 billion (down 3.79% YoY), while the FY2025 annual figure was $2.5 billion, down 5.94% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $2.5 billion, up from $2.5 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $2.7 billion in Q3 2023, with the low at $2.3 billion in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $2.6 billion (2023), against an average of $2.6 billion.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities increased 17.39% in 2023, then declined 7.87% in 2025.
- Bio-Techne's Total Non-Current Liabilities stood at $2.4 billion in 2022, then advanced by 15.36% to $2.7 billion in 2023, then dropped by 2.0% to $2.7 billion in 2024, then decreased by 6.0% to $2.5 billion in 2025, then gained by 1.17% to $2.5 billion in 2026.
- Business Quant data shows TECH's Total Non-Current Liabilities at $2.5 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 2.53 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.53 Bn |
| Dec 31, 2025 | 2.50 Bn |
| Sep 30, 2025 | 2.50 Bn |
| Jun 30, 2025 | 2.53 Bn |
| Mar 31, 2025 | 2.63 Bn |
| Dec 31, 2024 | 2.66 Bn |
| Sep 30, 2024 | 2.72 Bn |
| Jun 30, 2024 | 2.69 Bn |
| Mar 31, 2024 | 2.71 Bn |
| Dec 31, 2023 | 2.71 Bn |
| Sep 30, 2023 | 2.75 Bn |
| Jun 30, 2023 | 2.63 Bn |
| Mar 31, 2023 | 2.59 Bn |
| Dec 31, 2022 | 2.35 Bn |
| Sep 30, 2022 | 2.34 Bn |
| Jun 30, 2022 | 2.29 Bn |
| Mar 31, 2022 | 2.29 Bn |
| Dec 31, 2021 | 2.30 Bn |
| Sep 30, 2021 | 2.25 Bn |
| Jun 30, 2021 | 2.24 Bn |